Pharma Commercial Mock
← All views
Competitive intelligence

CI feed

Conference abstracts + payer decisions interleaved chronologically — the CI team aims to publish a structured briefing within 48 hours of any high-relevance event landing here.

103 items in window · 103 high-relevance

type:allabstractspayer decisionsrelevance:allhighmediumlow
  1. Payerhigh (91%)cms lcdcoverage decision
    2025-06-01
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JFlives: 4,361,966effective: 2025-06-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  2. Payerhigh (88%)icervalue assessment draft
    2025-06-02
    ICER released draft evidence report on ZENVARA for NSCLC.
    ICERUS-nationallives: 50,803,475effective: 2025-06-02
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: C+value_for_money: high
  3. Payerhigh (73%)cms lcdcoverage decision
    2025-06-03
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J8lives: 8,889,156effective: 2025-06-03
    Decision targets ZENVARA's direct competitor in NSCLC.
  4. Payerhigh (77%)pbm commercialtier changed
    2025-06-03
    Express Scripts moved ZENVARA from preferred to non-preferred tier.
    Express ScriptsUS-nationallives: 98,664,512effective: 2025-06-03
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 5
  5. Payerhigh (89%)health plan commercialrestriction added
    2025-06-04
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 12,182,866effective: 2025-07-20
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  6. Payerhigh (70%)state medicaid pdlremoved
    2025-06-04
    Florida AHCA removed ZENVARA from formulary effective 2025-07-28.
    Florida AHCAUS-state:MIlives: 7,061,543effective: 2025-07-28
    Decision targets ZENVARA's direct competitor in NSCLC.
  7. Payerhigh (92%)health plan commercialrestriction added
    2025-06-05
    UnitedHealthcare added prior-authorization requirement to ZENVARA.
    UnitedHealthcareUS-nationallives: 8,642,708effective: 2025-06-05
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA,ST
  8. Payerhigh (72%)state medicaid pdladded
    2025-06-05
    Florida AHCA added ZENVARA to NSCLC formulary tier 3 with PA.
    Florida AHCAUS-state:OHlives: 11,627,914effective: 2025-07-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  9. Payerhigh (91%)health plan commercialrestriction added
    2025-06-05
    UnitedHealthcare added prior-authorization requirement to ZENVARA.
    UnitedHealthcareUS-nationallives: 11,134,149effective: 2025-07-11
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: ST,QL
  10. Payerhigh (87%)pbm commercialstep therapy imposed
    2025-06-06
    Express Scripts now requires step therapy through alternative before ZENVARA.
    Express ScriptsUS-nationallives: 82,929,630effective: 2025-06-11
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  11. Payerhigh (71%)pbm medicare pdpremoved
    2025-06-09
    CVS Caremark SilverScript removed ZENVARA from formulary effective 2025-06-20.
    CVS Caremark SilverScriptUS-nationallives: 10,197,183effective: 2025-06-20
    Decision targets ZENVARA's direct competitor in NSCLC.
  12. Payerhigh (81%)state medicaid pdladded
    2025-06-10
    Ohio DODD added ZENVARA to NSCLC formulary tier 3 with PA.
    Ohio DODDUS-state:MIlives: 13,722,489effective: 2025-07-15
    Decision targets ZENVARA's direct competitor in NSCLC.
  13. Payerhigh (79%)pbm commercialstep therapy imposed
    2025-06-10
    CVS Caremark now requires step therapy through alternative before ZENVARA.
    CVS CaremarkUS-nationallives: 70,948,713effective: 2025-06-29
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  14. Payerhigh (87%)hta intlvalue assessment final
    2025-06-11
    CADTH (Canada) published final value assessment for ZENVARA in NSCLC.
    CADTH (Canada)UKlives: 47,166,600effective: 2025-06-11
    Decision targets ZENVARA's direct competitor in NSCLC.
  15. Payerhigh (73%)pbm commercialrestriction added
    2025-06-12
    CVS Caremark added prior-authorization requirement to ZENVARA.
    CVS CaremarkUS-nationallives: 73,132,320effective: 2025-07-10
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL,LA
  16. Payerhigh (72%)state medicaid pdladded
    2025-06-12
    California DHCS added ZENVARA to NSCLC formulary tier 3 with PA.
    California DHCSUS-state:FLlives: 5,773,802effective: 2025-07-20
    Decision targets ZENVARA's direct competitor in NSCLC.
  17. Payerhigh (88%)hta intlcoverage decision
    2025-06-13
    CADTH (Canada) issued coverage decision for ZENVARA in NSCLC.
    CADTH (Canada)UKlives: 41,898,018effective: 2025-06-13
    Decision targets ZENVARA's direct competitor in NSCLC.
  18. Payerhigh (95%)cms lcdcoverage decision
    2025-06-14
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 3,580,272effective: 2025-06-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  19. Payerhigh (89%)icervalue assessment draft
    2025-06-16
    ICER released draft evidence report on ZENVARA for NSCLC.
    ICERUS-nationallives: 55,776,217effective: 2025-06-16
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: Avalue_for_money: intermediateprice_benchmark_usd: 98748
  20. Payerhigh (74%)state medicaid pdladded
    2025-06-16
    Pennsylvania DHS added ZENVARA to NSCLC formulary tier 3 with PA.
    Pennsylvania DHSUS-state:MIlives: 10,609,773effective: 2025-06-18
    Decision targets ZENVARA's direct competitor in NSCLC.
  21. Payerhigh (79%)hta intlvalue assessment final
    2025-06-16
    HAS (France) published final value assessment for ZENVARA in NSCLC.
    HAS (France)EU-DElives: 6,716,500effective: 2025-06-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  22. Payerhigh (77%)state medicaid pdladded
    2025-06-17
    Pennsylvania DHS added ZENVARA to NSCLC formulary tier 3 with PA.
    Pennsylvania DHSUS-state:MIlives: 7,897,252effective: 2025-08-09
    Decision targets ZENVARA's direct competitor in NSCLC.
  23. Payerhigh (78%)pbm medicare pdptier changed
    2025-06-23
    Humana Pharmacy Solutions moved ZENVARA from preferred to non-preferred tier.
    Humana Pharmacy SolutionsUS-nationallives: 5,763,465effective: 2025-06-28
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  24. Payerhigh (94%)cms ncdcoverage decision
    2025-06-23
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 66,588,984effective: 2025-06-23
    Decision targets ZENVARA's direct competitor in NSCLC.
  25. Payerhigh (93%)cms ncdcoverage decision
    2025-06-24
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 66,220,974effective: 2025-06-24
    Decision targets ZENVARA's direct competitor in NSCLC.
  26. Payerhigh (92%)pbm commercialrestriction added
    2025-06-27
    CVS Caremark added prior-authorization requirement to ZENVARA.
    CVS CaremarkUS-nationallives: 85,978,174effective: 2025-06-30
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  27. Payerhigh (76%)state medicaid pdladded
    2025-06-27
    Florida AHCA added ZENVARA to NSCLC formulary tier 3 with PA.
    Florida AHCAUS-state:FLlives: 12,685,899effective: 2025-07-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  28. Payerhigh (75%)pbm commercialtier changed
    2025-06-30
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 85,127,933effective: 2025-07-07
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 4
  29. Payerhigh (94%)health plan commercialrestriction removed
    2025-07-01
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 11,057,130effective: 2025-07-01
    Decision targets ZENVARA's direct competitor in NSCLC.
  30. Payerhigh (73%)hta intlvalue assessment final
    2025-07-02
    NICE (UK) published final value assessment for ZENVARA in NSCLC.
    NICE (UK)EU-FRlives: 51,472,238effective: 2025-07-02
    Decision targets ZENVARA's direct competitor in NSCLC.
  31. Payerhigh (73%)health plan commercialrestriction added
    2025-07-03
    BCBS Federal Employee Program added prior-authorization requirement to ZENVARA.
    BCBS Federal Employee ProgramUS-nationallives: 6,850,548effective: 2025-07-07
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  32. Payerhigh (83%)icervalue assessment final
    2025-07-04
    ICER published final value assessment for ZENVARA in NSCLC.
    ICERUS-nationallives: 65,882,802effective: 2025-07-04
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: C+value_for_money: highprice_benchmark_usd: 155336
  33. Payerhigh (70%)hospital pt committeerestriction added
    2025-07-06
    Ascension added prior-authorization requirement to ZENVARA.
    AscensionUS-nationallives: 636,467effective: 2025-07-21
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA,PA
  34. Payerhigh (72%)pbm medicare pdpadded
    2025-07-07
    Humana Pharmacy Solutions added ZENVARA to NSCLC formulary tier 3 with PA.
    Humana Pharmacy SolutionsUS-nationallives: 8,421,949effective: 2025-08-17
    Decision targets ZENVARA's direct competitor in NSCLC.
  35. Payerhigh (70%)health plan commercialtier changed
    2025-07-07
    BCBS Federal Employee Program moved ZENVARA from preferred to non-preferred tier.
    BCBS Federal Employee ProgramUS-nationallives: 21,664,802effective: 2025-08-13
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  36. Payerhigh (86%)pbm medicare pdpadded
    2025-07-07
    CVS Caremark SilverScript added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS Caremark SilverScriptUS-nationallives: 7,969,893effective: 2025-07-19
    Decision targets ZENVARA's direct competitor in NSCLC.
  37. Payerhigh (91%)health plan commercialtier changed
    2025-07-08
    Aetna moved ZENVARA from preferred to non-preferred tier.
    AetnaUS-nationallives: 24,735,149effective: 2025-09-04
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 3
  38. Payerhigh (70%)hta intlcoverage decision
    2025-07-08
    NICE (UK) issued coverage decision for ZENVARA in NSCLC.
    NICE (UK)EU-FRlives: 44,125,340effective: 2025-07-08
    Decision targets ZENVARA's direct competitor in NSCLC.
  39. Payerhigh (82%)pbm commercialrestriction added
    2025-07-16
    Express Scripts added prior-authorization requirement to ZENVARA.
    Express ScriptsUS-nationallives: 97,353,887effective: 2025-09-01
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: ST,LA
  40. Payerhigh (89%)pbm medicare pdprestriction added
    2025-07-17
    Express Scripts Medicare added prior-authorization requirement to ZENVARA.
    Express Scripts MedicareUS-nationallives: 10,469,373effective: 2025-08-27
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: ST,PA
  41. Payerhigh (75%)health plan commercialrestriction added
    2025-07-20
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 9,210,226effective: 2025-09-13
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL,ST
  42. Payerhigh (90%)hospital pt committeeadded
    2025-07-20
    Kaiser Hospitals added ZENVARA to NSCLC formulary tier 3 with PA.
    Kaiser HospitalsUS-nationallives: 1,371,864effective: 2025-09-12
    Decision targets ZENVARA's direct competitor in NSCLC.
  43. Payerhigh (75%)state medicaid pdladded
    2025-07-21
    Ohio DODD added ZENVARA to NSCLC formulary tier 3 with PA.
    Ohio DODDUS-state:ILlives: 12,779,672effective: 2025-09-03
    Decision targets ZENVARA's direct competitor in NSCLC.
  44. Payerhigh (95%)pbm medicare pdpremoved
    2025-07-22
    Humana Pharmacy Solutions removed ZENVARA from formulary effective 2025-09-16.
    Humana Pharmacy SolutionsUS-nationallives: 5,600,467effective: 2025-09-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  45. Payerhigh (93%)cms lcdcoverage decision
    2025-07-23
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JFlives: 11,182,172effective: 2025-07-23
    Decision targets ZENVARA's direct competitor in NSCLC.
  46. Payerhigh (79%)cms lcdcoverage decision
    2025-07-25
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J5lives: 5,566,890effective: 2025-07-25
    Decision targets ZENVARA's direct competitor in NSCLC.
  47. Payerhigh (93%)cms lcdcoverage decision
    2025-07-27
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J6lives: 5,979,461effective: 2025-07-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  48. Payerhigh (78%)pbm commercialtier changed
    2025-08-03
    CVS Caremark moved ZENVARA from preferred to non-preferred tier.
    CVS CaremarkUS-nationallives: 90,521,897effective: 2025-09-12
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 5
  49. Payerhigh (79%)cms lcdcoverage decision
    2025-08-03
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JFlives: 5,230,248effective: 2025-08-03
    Decision targets ZENVARA's direct competitor in NSCLC.
  50. Payerhigh (74%)health plan commercialrestriction removed
    2025-08-08
    UnitedHealthcare removed step-therapy requirement on ZENVARA.
    UnitedHealthcareUS-nationallives: 6,988,605effective: 2025-08-08
    Decision targets ZENVARA's direct competitor in NSCLC.
  51. Payerhigh (95%)pbm commercialrestriction added
    2025-08-08
    Express Scripts added prior-authorization requirement to ZENVARA.
    Express ScriptsUS-nationallives: 85,126,875effective: 2025-09-27
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA
  52. Payerhigh (74%)pbm medicare pdptier changed
    2025-08-10
    OptumRx Medicare moved ZENVARA from preferred to non-preferred tier.
    OptumRx MedicareUS-nationallives: 3,635,948effective: 2025-09-10
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 3tier_after: 3
  53. Payerhigh (81%)pbm commercialrestriction added
    2025-08-10
    Express Scripts added prior-authorization requirement to ZENVARA.
    Express ScriptsUS-nationallives: 99,063,045effective: 2025-08-29
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA
  54. Payerhigh (85%)health plan commercialrestriction added
    2025-08-10
    Kaiser Permanente added prior-authorization requirement to ZENVARA.
    Kaiser PermanenteUS-nationallives: 18,594,702effective: 2025-09-06
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA,PA
  55. Payerhigh (82%)state medicaid pdlpdl preferred status changed
    2025-08-11
    Florida AHCA updated PDL preferred status for ZENVARA.
    Florida AHCAUS-state:ILlives: 5,134,104effective: 2025-08-11
    Decision targets ZENVARA's direct competitor in NSCLC.
  56. Payerhigh (89%)cms lcdcoverage decision
    2025-08-14
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 9,797,625effective: 2025-08-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  57. Payerhigh (78%)pbm medicare pdpremoved
    2025-08-15
    OptumRx Medicare removed ZENVARA from formulary effective 2025-10-06.
    OptumRx MedicareUS-nationallives: 3,364,598effective: 2025-10-06
    Decision targets ZENVARA's direct competitor in NSCLC.
  58. Payerhigh (73%)pbm medicare pdptier changed
    2025-08-15
    Humana Pharmacy Solutions moved ZENVARA from preferred to non-preferred tier.
    Humana Pharmacy SolutionsUS-nationallives: 10,563,302effective: 2025-09-11
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  59. Payerhigh (72%)dod tricareremoved
    2025-08-16
    DoD TRICARE removed ZENVARA from formulary effective 2025-09-02.
    DoD TRICAREUS-nationallives: 9,785,143effective: 2025-09-02
    Decision targets ZENVARA's direct competitor in NSCLC.
  60. Payerhigh (71%)hta intlvalue assessment final
    2025-08-16
    CADTH (Canada) published final value assessment for ZENVARA in NSCLC.
    CADTH (Canada)UKlives: 39,347,094effective: 2025-08-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  61. Payerhigh (86%)icerprice benchmark
    2025-08-16
    ICER updated value-based price benchmark for ZENVARA.
    ICERUS-nationallives: 75,918,902effective: 2025-08-16
    Decision targets ZENVARA's direct competitor in NSCLC.
    price_benchmark_usd: 66661value_for_money: low
  62. Payerhigh (72%)cms lcdcoverage decision
    2025-08-18
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JLlives: 8,163,922effective: 2025-08-18
    Decision targets ZENVARA's direct competitor in NSCLC.
  63. Payerhigh (72%)pbm commercialadded
    2025-08-18
    CVS Caremark added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS CaremarkUS-nationallives: 77,995,825effective: 2025-10-06
    Decision targets ZENVARA's direct competitor in NSCLC.
  64. Payerhigh (80%)pbm commercialtier changed
    2025-08-21
    OptumRx moved ZENVARA from preferred to non-preferred tier.
    OptumRxUS-nationallives: 89,496,886effective: 2025-09-13
    Decision targets ZENVARA's direct competitor in NSCLC.
    tier_before: 2tier_after: 4
  65. Payerhigh (91%)state medicaid pdladded
    2025-08-25
    Texas HHSC added ZENVARA to NSCLC formulary tier 3 with PA.
    Texas HHSCUS-state:MIlives: 8,291,671effective: 2025-08-30
    Decision targets ZENVARA's direct competitor in NSCLC.
  66. Payerhigh (87%)pbm commercialstep therapy imposed
    2025-08-27
    Express Scripts now requires step therapy through alternative before ZENVARA.
    Express ScriptsUS-nationallives: 78,263,110effective: 2025-09-23
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: LA,QL
  67. Payerhigh (71%)hospital pt committeeadded
    2025-08-28
    HCA Healthcare added ZENVARA to NSCLC formulary tier 3 with PA.
    HCA HealthcareUS-nationallives: 671,490effective: 2025-10-09
    Decision targets ZENVARA's direct competitor in NSCLC.
  68. Payerhigh (72%)state medicaid pdladded
    2025-08-30
    Texas HHSC added ZENVARA to NSCLC formulary tier 3 with PA.
    Texas HHSCUS-state:FLlives: 8,125,512effective: 2025-09-12
    Decision targets ZENVARA's direct competitor in NSCLC.
  69. Payerhigh (92%)icervalue assessment final
    2025-09-02
    ICER published final value assessment for ZENVARA in NSCLC.
    ICERUS-nationallives: 52,097,687effective: 2025-09-02
    Decision targets ZENVARA's direct competitor in NSCLC.
    rating: Avalue_for_money: intermediate
  70. Payerhigh (73%)hta intlcoverage decision
    2025-09-04
    HAS (France) issued coverage decision for ZENVARA in NSCLC.
    HAS (France)EU-DElives: 53,487,154effective: 2025-09-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  71. Payerhigh (75%)cms ncdcoverage decision
    2025-09-05
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 63,826,503effective: 2025-09-05
    Decision targets ZENVARA's direct competitor in NSCLC.
  72. Payerhigh (71%)va national formularyremoved
    2025-09-06
    VA Pharmacy Benefits Management removed ZENVARA from formulary effective 2025-10-11.
    VA Pharmacy Benefits ManagementUS-nationallives: 8,895,017effective: 2025-10-11
    Decision targets ZENVARA's direct competitor in NSCLC.
  73. Payerhigh (74%)hospital pt committeeremoved
    2025-09-11
    HCA Healthcare removed ZENVARA from formulary effective 2025-09-27.
    HCA HealthcareUS-nationallives: 813,935effective: 2025-09-27
    Decision targets ZENVARA's direct competitor in NSCLC.
  74. Payerhigh (75%)hospital pt committeeadded
    2025-09-12
    HCA Healthcare added ZENVARA to NSCLC formulary tier 3 with PA.
    HCA HealthcareUS-nationallives: 346,505effective: 2025-09-16
    Decision targets ZENVARA's direct competitor in NSCLC.
  75. Payerhigh (93%)health plan commercialrestriction removed
    2025-09-14
    Cigna removed step-therapy requirement on ZENVARA.
    CignaUS-nationallives: 9,077,183effective: 2025-09-14
    Decision targets ZENVARA's direct competitor in NSCLC.
  76. Payerhigh (84%)hospital pt committeerestriction added
    2025-09-18
    CommonSpirit Health added prior-authorization requirement to ZENVARA.
    CommonSpirit HealthUS-nationallives: 726,705effective: 2025-11-11
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: QL
  77. Payerhigh (93%)state medicaid pdladded
    2025-09-18
    New York DOH added ZENVARA to NSCLC formulary tier 3 with PA.
    New York DOHUS-state:FLlives: 14,073,489effective: 2025-10-30
    Decision targets ZENVARA's direct competitor in NSCLC.
  78. Payerhigh (82%)cms lcdcoverage decision
    2025-09-21
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:J15lives: 7,273,679effective: 2025-09-21
    Decision targets ZENVARA's direct competitor in NSCLC.
  79. Payerhigh (81%)cms ncdcoverage decision
    2025-09-22
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSUS-nationallives: 66,899,922effective: 2025-09-22
    Decision targets ZENVARA's direct competitor in NSCLC.
  80. Payerhigh (80%)pbm medicare pdprestriction added
    2025-09-22
    Humana Pharmacy Solutions added prior-authorization requirement to ZENVARA.
    Humana Pharmacy SolutionsUS-nationallives: 8,430,961effective: 2025-10-31
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA,LA
  81. Payerhigh (86%)pbm medicare pdpadded
    2025-09-24
    CVS Caremark SilverScript added ZENVARA to NSCLC formulary tier 3 with PA.
    CVS Caremark SilverScriptUS-nationallives: 3,284,583effective: 2025-10-18
    Decision targets ZENVARA's direct competitor in NSCLC.
  82. Payerhigh (72%)hospital pt committeeremoved
    2025-09-25
    HCA Healthcare removed ZENVARA from formulary effective 2025-11-22.
    HCA HealthcareUS-nationallives: 1,850,028effective: 2025-11-22
    Decision targets ZENVARA's direct competitor in NSCLC.
  83. Payerhigh (70%)pbm medicare pdpadded
    2025-09-25
    Humana Pharmacy Solutions added ZENVARA to NSCLC formulary tier 3 with PA.
    Humana Pharmacy SolutionsUS-nationallives: 6,984,777effective: 2025-10-04
    Decision targets ZENVARA's direct competitor in NSCLC.
  84. Payerhigh (89%)pbm medicare pdprestriction added
    2025-10-02
    OptumRx Medicare added prior-authorization requirement to ZENVARA.
    OptumRx MedicareUS-nationallives: 3,879,342effective: 2025-11-18
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: ST,LA
  85. Payerhigh (70%)pbm commercialrestriction added
    2025-10-05
    CVS Caremark added prior-authorization requirement to ZENVARA.
    CVS CaremarkUS-nationallives: 69,477,806effective: 2025-11-27
    Decision targets ZENVARA's direct competitor in NSCLC.
    restrictions: PA
  86. Payerhigh (86%)cms lcdcoverage decision
    2025-10-06
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JJlives: 5,335,531effective: 2025-10-06
    Decision targets ZENVARA's direct competitor in NSCLC.
  87. Payerhigh (92%)cms lcdcoverage decision
    2025-10-09
    CMS issued coverage decision for ZENVARA in NSCLC.
    CMSMAC:JLlives: 11,298,477effective: 2025-10-09
    Decision targets ZENVARA's direct competitor in NSCLC.
  88. Congresshighembargo lifts in 1d
    Jun 1, 2026, 4:00 PM
    Real-world effectiveness of Kisqali vs standard of care in HR+ breast cancer
    Median OS 33.8 months. HR 0.8 (95% CI 0.71–0.89). No new safety signals identified.
    Kisqali () · NovartisHR+ breast cancerMONALEESA-38 · NCT60056504Poster Discussion Session
    OS
    33.8 months
    HR 0.8 (0.71-0.89)
    PFS
    22.8 months
    HR 0.77 (0.69-0.86)
    ORR
    77.9 percent
  89. Congresshighembargo lifts in 1d
    Jun 1, 2026, 4:15 PM
    Real-world effectiveness of Enhertu vs standard of care in NSCLC
    Median OS 29.4 months. HR 0.85 (95% CI 0.76–0.94). Grade ≥3 AEs consistent with prior reports.
    Enhertu () · Daiichi SankyoNSCLCDESTINY-Breast-376 · NCT30918589Poster Session
    OS
    29.4 months
    HR 0.85 (0.76-0.94)
    PFS
    7.2 months
    HR 0.89 (0.8-0.91)
    ORR
    50.6 percent
  90. Congresshighembargo lifts in 2d
    Jun 2, 2026, 3:45 PM
    Long-term follow-up of Ibrance 1L for HR+ breast cancer: PALOMA-349
    Median OS 37.6 months. HR 0.68 (95% CI 0.56–0.8). No new safety signals identified.
    Ibrance () · PfizerHR+ breast cancerPALOMA-349 · NCT90598054Oral Abstract Session
    OS
    37.6 months
    HR 0.68 (0.56-0.8)
    PFS
    23.6 months
    HR 0.67 (0.53-0.78)
    ORR
    78 percent
  91. Congresshighembargo lifts in 2d
    Jun 2, 2026, 4:00 PM
    Biomarker subgroup analysis of Tagrisso in NSCLC (the FLAURA-312 study)
    Median OS 28.5 months. HR 0.68 (95% CI 0.55–0.81). Grade ≥3 AEs consistent with prior reports.
    Tagrisso () · AstraZenecaNSCLCFLAURA-312 · NCT74476517Rapid Oral Abstract Session
    OS
    28.5 months
    HR 0.68 (0.55-0.81)
    PFS
    8.8 months
    HR 0.69 (0.54-0.82)
    ORR
    44.2 percent
  92. Congresshighembargo lifts in 2d
    Jun 2, 2026, 8:30 PM
    Quality of life outcomes with Kisqali in patients with HR+ breast cancer
    Median OS 35.6 months. HR 0.7 (95% CI 0.62–0.78). Grade ≥3 AEs consistent with prior reports.
    Kisqali () · NovartisHR+ breast cancerMONALEESA-190 · NCT77693036Poster Session
    OS
    35.6 months
    HR 0.7 (0.62-0.78)
    PFS
    20.5 months
    HR 0.74 (0.66-0.81)
    ORR
    55.5 percent
  93. Congresshighembargo lifts in 3d
    Jun 3, 2026, 3:30 PM
    FLAURA-898: Tagrisso (osimertinib) 2L in NSCLC
    Median OS 22.5 months. HR 0.76 (95% CI 0.66–0.86). Grade ≥3 AEs consistent with prior reports.
    Tagrisso () · AstraZenecaNSCLCFLAURA-898 · NCT65454622Poster Session
    OS
    22.5 months
    HR 0.76 (0.66-0.86)
    PFS
    10.5 months
    HR 0.76 (0.68-0.84)
    ORR
    59.6 percent
  94. Congresshighembargo lifts in 3d
    Jun 3, 2026, 3:45 PM
    Biomarker subgroup analysis of Verzenio in HR+ breast cancer (the MONARCH-410 study)
    Median OS 36.7 months. HR 0.9 (95% CI 0.77–0.99). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-410 · NCT12503018Oral Abstract Session
    OS
    36.7 months
    HR 0.9 (0.77-0.99)
    PFS
    22.3 months
    HR 0.93 (0.8-0.99)
    ORR
    58.8 percent
  95. Congresshighembargo lifts in 4d
    Jun 4, 2026, 2:00 PM
    Long-term follow-up of Opdivo 3L+ for NSCLC: CheckMate-881
    Median OS 29.3 months. HR 0.6 (95% CI 0.51–0.69). No new safety signals identified.
    Opdivo () · Bristol-Myers SquibbNSCLCCheckMate-881 · NCT08001951Poster Session
    OS
    29.3 months
    HR 0.6 (0.51-0.69)
    PFS
    7.4 months
    HR 0.61 (0.51-0.72)
    ORR
    60 percent
  96. Congresshighembargo lifts in 4d
    Jun 4, 2026, 4:30 PM
    Imfinzi plus chemotherapy in previously untreated biliary tract: updated analysis from PACIFIC-190
    Median OS 12.7 months. HR 0.83 (95% CI 0.72–0.94). Grade ≥3 AEs consistent with prior reports.
    Imfinzi () · AstraZenecabiliary tractPACIFIC-190 · NCT97449766Poster Session
    OS
    12.7 months
    HR 0.83 (0.72-0.94)
    PFS
    7.5 months
    HR 0.83 (0.69-0.97)
    ORR
    34.7 percent
  97. Congresshighembargo lifts in 4d
    Jun 4, 2026, 5:00 PM
    Keytruda plus chemotherapy in previously untreated NSCLC: updated analysis from KEYNOTE-645
    Median OS 22.4 months. HR 0.6 (95% CI 0.5–0.7). Grade ≥3 AEs consistent with prior reports.
    Keytruda () · MerckNSCLCKEYNOTE-645 · NCT22264892Poster Discussion Session
    OS
    22.4 months
    HR 0.6 (0.5-0.7)
    PFS
    7.7 months
    HR 0.64 (0.49-0.67)
    ORR
    45.7 percent
  98. Congresshighembargo lifts in 4d
    Jun 4, 2026, 7:45 PM
    Quality of life outcomes with Keytruda in patients with NSCLC
    Median OS 25.6 months. HR 0.79 (95% CI 0.7–0.88). Grade ≥3 AEs consistent with prior reports.
    Keytruda () · MerckNSCLCKEYNOTE-433 · NCT65945184Poster Session
    OS
    25.6 months
    HR 0.79 (0.7-0.88)
    PFS
    11.7 months
    HR 0.77 (0.66-0.89)
    ORR
    61.9 percent
  99. Congresshighembargo lifts in 5d
    Jun 5, 2026, 2:15 PM
    Quality of life outcomes with Ibrance in patients with HR+ breast cancer
    Median OS 38.2 months. HR 0.9 (95% CI 0.8–0.99). No new safety signals identified.
    Ibrance () · PfizerHR+ breast cancerPALOMA-223 · NCT98838794Oral Abstract Session
    OS
    38.2 months
    HR 0.9 (0.8-0.99)
    PFS
    27.1 months
    HR 0.86 (0.8-0.95)
    ORR
    57.2 percent
  100. Congresshighembargo lifts in 5d
    Jun 5, 2026, 5:00 PM
    Real-world effectiveness of Verzenio vs standard of care in HR+ breast cancer
    Median OS 38.9 months. HR 0.58 (95% CI 0.47–0.69). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-149 · NCT32526973Oral Abstract Session
    OS
    38.9 months
    HR 0.58 (0.47-0.69)
    PFS
    19.4 months
    HR 0.6 (0.48-0.7)
    ORR
    74.7 percent
  101. Congresshighembargo lifts in 5d
    Jun 5, 2026, 5:30 PM
    Biomarker subgroup analysis of Imfinzi in SCLC (the PACIFIC-419 study)
    Median OS 14.9 months. HR 0.83 (95% CI 0.74–0.92). No new safety signals identified.
    Imfinzi () · AstraZenecaSCLCPACIFIC-419 · NCT88358487Oral Abstract Session
    OS
    14.9 months
    HR 0.83 (0.74-0.92)
    PFS
    6.1 months
    HR 0.81 (0.76-0.89)
    ORR
    63 percent
  102. Congresshighembargo lifts in 5d
    Jun 5, 2026, 9:30 PM
    MONARCH-789: Verzenio (abemaciclib) neoadjuvant in HR+ breast cancer
    Median OS 37.2 months. HR 0.87 (95% CI 0.75–0.99). No new safety signals identified.
    Verzenio () · Eli LillyHR+ breast cancerMONARCH-789 · NCT81284428Rapid Oral Abstract Session
    OS
    37.2 months
    HR 0.87 (0.75-0.99)
    PFS
    24.7 months
    HR 0.85 (0.74-0.99)
    ORR
    58.8 percent
  103. Congresshighembargo lifts in 5d
    Jun 5, 2026, 10:00 PM
    Long-term follow-up of Tecentriq maintenance for TNBC: IMpower-449
    Median OS 23.5 months. HR 0.86 (95% CI 0.75–0.97). No new safety signals identified.
    Tecentriq () · RocheTNBCIMpower-449 · NCT18767167Poster Session
    OS
    23.5 months
    HR 0.86 (0.75-0.97)
    PFS
    9.9 months
    HR 0.87 (0.73-0.98)
    ORR
    50.8 percent